The analytical performance of the Tandem ® -R free PSA assay available from Hybritech Inc. was evaluated. Comparison of recoveries of purified free (unbound) prostate-specific antigen (PSA) diluted in female serum in the Tandem-R free PSA assay and the Tandem-R (total) PSA assay demonstrated a link in calibration between the assays and an accurate determination of percent free PSA. The cross-reactivity of the assay to purified PSA-␣ 1 -antichymotrypsin was determined to be <1%. The minimum-detectable concentration was <0.05 g/L. The within-run and between-day CVs were <5% for samples with >0.3 g/L free PSA. Dilution and recovery showed no significant deviations from linearity across the assay range. The assay was insensitive to interference from blood components. The Tandem-R free PSA kit was shown to be an accurate, precise, and reliable assay for the measurement of free PSA. INDEXING TERMS: tumor markers • prostate cancer
Prostate-specific antigen (PSA) 1 is a single-chain kallikrein produced by the epithelial cells of the prostate; it has serine protease activity and an apparent molecular mass of ϳ30 -36 kDa [1] [2] [3] [4] . PSA has been shown to form complexes with ␣ 1 -antichymotrypsin (ACT), ␣ 2 -macroglobulin (␣ 2 M), and other binding proteins [5] . Total PSA (i.e., all of the immunologically detectable forms, consisting primarily of PSA-ACT and free PSA) has served as an excellent indicator of prostate disease when the concentration exceeds 4.0 g/L in serum [6] . However, distinguishing prostate cancer from benign prostatic hyperplasia is clinically imprecise [7] . Recent studies have suggested that PSA forms may have clinical value for distinguishing prostate cancer from benign prostatic hyperplasia [8 -15] . In particular, the use of the percent of free PSA [% ϭ (free PSA/total PSA) ϫ 100], as determined by Tandem ® -R free PSA assay in conjunction with Tandem-R (total) PSA assay (both from Hybritech Inc.), can improve the clinical specificity of PSA testing such that between 20% and 64% of negative biopsies may be avoided with only a 5-10% decrease in the cancer detection rate [13] [14] [15] .
Differences in the relative proportions of free PSA and PSA-ACT affect the results of some total PSA assays [16] . In addition, differences in the calibration and performance of free PSA assays have been reported recently [17, 18] . These reports imply that the values derived for percent free PSA and the attendant cutoffs used are dependent on which free PSA and total PSA assays are used. This study was performed to characterize the analytical performance and calibration of the Tandem-R free PSA assay and the percent free PSA value obtained by using the Tandem-R free PSA and Tandem-R (total) PSA assay systems.
Materials and Methods assay methods
We determined total PSA concentrations with the Tandem-R PSA assay and free PSA concentrations with the Tandem-R free PSA assay (Hybritech Inc., San Diego, CA), following the recommended protocols of the manufacturer. Both assays are solid-phase, two-site IRMAs. Samples containing analyte are reacted with a plastic bead coated with a monoclonal antibody directed toward a particular epitope on the PSA molecule and with a radiolabeled monoclonal antibody directed toward a second distinct epitope. After formation of the solid-phase/ analyte/labeled-antibody sandwich, the bead is washed to remove unbound labeled antibody. The amount of radioactivity bound to the bead is proportional to the amount of analyte present in the test sample, which is determined from a calibrated curve by using a linear or cubic spline equation to interpolate between calibrators. The current Tandem-R free PSA assay should not be confused with earlier research prototypes previously reported by Wang et al. [19] . The research prototype was a sequential assay using streptavidin-coated microplates, biotinylated anti-free PSA (PSB999), and europium-labeled anti-PSA (PSM773). Tandem-R free PSA assay is a simultaneous assay using radiolabeled anti-free PSA (PSB999) and a different anti-PSA (PSA399) antibody coated onto a plastic bead.
purified free psa and psa-act
Purified PSA-ACT and free PSA were prepared by the method of Sensabaugh and Blake [20] . Seminal fluid PSA was incubated with a 6-fold molar excess of ACT (Athens Research and Technology, Athens, GA) for 18 h at 37°C in Tris-buffered saline, pH 7.4, and fractionated over a poly(propylaspartamide) hydrophobic interaction chromatographic column (PolyLC) in a gradient of 1.2 mol/L sodium sulfate, 0.02 mol/L sodium phosphate, pH 6.3, and 0.05 mol/L sodium phosphate, 50 mL/L isopropanol, pH 7.3. Baseline resolution between PSA (ϳ34 kDa), PSA-ACT (ϳ90 kDa), and ACT (ϳ55 kDa) was observed. The concentrations of free PSA and total PSA were measured in each fraction by the free and total PSA assays, as described below. Fractions were pooled on the basis of immunoreactivity and stored in 0.1 mol/L ammonium acetate at Ϫ70°C.
assay calibration and analytical recovery
For accurate percent free PSA results, the free PSA assay should be calibrated in agreement with the total PSA assay used so that a sample that contained only free PSA would be recovered identically in both assays. Thus, the calibration of the two assays would be analytically linked to each other and would provide a meaningful ratio of free to total PSA. To demonstrate this, purified free PSA was added to normal female serum treated to inactivate PSA-binding proteins according to the method of Berger and Ivor [21] to mimic hypothetical samples of 100% free PSA from 0 to 15 g/L free PSA. These samples were then run in both the Tandem-R (total) PSA and Tandem-R free PSA assays. The recovery of the purified free PSA in treated female serum was calculated relative to the amount of analyte added. The correlation and bias between values recovered in the two assays were determined by linear regression.
analytical performance studies Specificity. Dilutions of purified free PSA and PSA-ACT were prepared in treated female serum in a range of 1-100 g/L. The Tandem-R free PSA and Tandem-R (total) PSA assays were run in triplicate. Specificity was calculated by comparing the relative reactivity of the purified free and PSA-ACT preparations in the free PSA assay and also by comparing the relative reactivity of the PSA-ACT preparation in the free PSA assay and in the total PSA assay.
Precision. The intraassay precision was determined by running 20 replicates of individual serum-based controls in a single assay. The interassay precision was determined by running serum-based controls in triplicate in 20 assays from a single kit lot. The interlot precision was determined by running serum-based controls in either 54 or 81 individual assays over multiple days, with multiple reagent lots, by multiple technicians. Results were compared with intersite data from seven laboratories across the country [22] .
Minimum detectable concentration (MDC). The MDC was determined for each of 27 assays as the concentration of free PSA corresponding to a signal 2 SD above the mean of 20 replicates of the zero calibrator. The overall MDC was determined as the mean MDC of the 27 assays plus 1 SD.
Linearity on dilution. Ten samples at representative free PSA concentrations between 2 and 40 g/L were used to prepare a minimum of four gravimetric dilutions of each specimen in zero calibrator/specimen diluent. All specimens and dilutions were run in four replicates. Linear regression was used to characterize the dilution series.
High-dose hook effect. Purified free PSA from seminal fluid was tested at concentrations of 10 -5000 g/L to determine the free PSA concentration that would cause the assay to "hook" back into the normal assay range.
Interfering substances. Various blood components and chemotherapeutic and prostate-related drugs were tested at concentrations at least 10-fold higher than the expected normal range of the component in blood. Additions of each interfering substance were made into zero diluent and three serum-based kit controls, which span the range of the assay. Eight replicates of each control with and without the test substance were run in the assay. A t-test was used to evaluate the statistical significance of any differences in free PSA values observed in the test samples.
Commercial control stability. Serum controls used routinely with total PSA assays from four manufacturers: Bio-Rad (Hercules, CA), CIBA Corning Diagnostics (Medfield, MA), Baxter Diagnostics, Dade ® (Miami, FL), and Medical Analysis Systems (MAS; Camarillo, CA) were evaluated.
Lyophilized controls were first reconstituted, and then all controls were assayed for free PSA (time 0) and stored at 4, 25, and Ϫ20°C. At prescribed times (8 h and 1, 2, 3, 4, and 7 days) representative aliquots were removed and assayed in triplicate with the Tandem-R free PSA immunoassay [23] .
Results

assay calibration and analytical recovery
The slope and correlation of the linear regression between the Tandem-R (total) PSA and Tandem-R free PSA assays when testing a sample of 100% free PSA was y ϭ 1.015x Ϫ 0.033 with an r 2 of 1.000 (Fig. 1) . These results indicate that the assay will recover the analyte accurately, and the calibrations of the two assays are directly linked such that a sample consisting of 100% free PSA would be recovered identically in both the Tandem-R free PSA and Tandem-R (total) PSA assays. The recovered values of purified free PSA added to treated female serum were 0.84 g/L (96% of added analyte), 1.77 g/L (102%), 4.31 g/L (99%), 8.75 g/L (101%), and 13.05 g/L (100%), with a mean recovery of 99.5% of added analyte.
analytical specificity
The specificity of the Tandem-R free PSA assay was determined by two independent methods. In the first method, the dose responses of purified free PSA and PSA-ACT were compared in the Tandem-R free PSA assay (Fig. 2) . Linear regression provided a slope estimate of 4058 cpm per 1 g/L of free PSA compared with 32 cpm per 1 g/L of PSA-ACT. The ratio of the two slopes of response in the Tandem-R free PSA assay yielded a cross-reactivity estimate of ϳ0.8%. In the second method, the purified PSA-ACT was run in both the Tandem-R free PSA and the Tandem-R (total) PSA assays. The ratio of the values recovered in the two assays resulted in an average cross-reactivity of 0.7%.
precision Intraassay precision was determined from a mean of 20 replicates of each control in a single assay with the following results: 0.22 g/L, CV ϭ 7.7%; 0.32 g/L, CV ϭ 3.5%; 1.05 g/L, CV ϭ 2.2%; 3.85 g/L, CV ϭ 1.7%; 4.62 g/L, CV ϭ 1.5%. The interassay precision, interlot precision, and interlaboratory precision are shown in Table 1 . Overall, the precision of the assay within runs and between runs was excellent, with CVs of 5% or less for samples with Ͼ0.3 g/L free PSA and 8% or less for samples with Ͻ0.3 g/L free PSA. In addition, the precision in control recovery between manufacturer's lots was determined with 27 unique kit lots comprised of 6 lots of beads, 6 lots of calibrators, and either 6 or 9 lots of tracer (54 or 81 assays, respectively). The CVs of the control recoveries over the course of the entire multilot comparison were Ͻ11% with values Ͻ1 g/L free PSA and Ͻ5% with values Ͼ1 g/L free PSA. These data suggest that the assay is highly reproducible from lot to lot. The reproducibility of the assay in seven laboratories around the country was demonstrated when CVs of the control recoveries over the course of the entire multilaboratory comparison were Ͻ12% with values Ͻ0.3 g/L free PSA and Ͻ6% with values Ͼ0.3 g/L free PSA [22] .
mdc
The individual MDCs of the 27 assays ranged from 0.01 to 0.04 g/L with a mean MDC of 0.02 g/L and SD of 0.01 g/L.
linearity on dilution
Ten samples with free PSA values from 4 to 28 g/L were used in a dilution series from 1:2 to 1:100 with undiluted sample. No dilutions recovering Յ0.2 g/L were used in the linearity calculations. Actual dilution factors used in calculations were derived from gravimetric data. Overall, individual recoveries of nine samples ranged from 97% to 114% of expected, r 2 Ն 0.998. One sample recovered consistently at 120% across the dilution series, r 2 ϭ 1.000.
The average recovery of all 10 samples was 108%.
high-dose hook effect
Samples of free PSA from 10 to 5000 g/L were run in the Tandem-R free PSA assay. The cpm bound in the assay continued to rise until a plateau was reached near 1000 g/L (total) PSA; beyond this, the response began to decline because of the hook effect and crossed back into the calibrator range of the assay at ϳ2500 g/L (total) PSA.
interfering substances 
Discussion
The Tandem-R free PSA assay is an accurate and robust assay that provides reproducible results within an assay, from assay to assay, lot to lot, and site to site. The detection limit of the assay expressed as MDC is Ͻ0.05 g/L. The cross-reactivity to PSA-ACT is Ͻ1% as determined by two independent methods of assessment. None of the blood components or drugs tested interfered with the performance of the assay. No substantial bias in linearity was observed when samples were diluted. The presence of PSA-binding proteins in serum makes traditional analytical recovery studies difficult. However, when purified, ACT-depleted seminal fluid PSA was added to female serum that had been treated to inactivate other PSA-binding proteins, the average recovery of free PSA was 99.5%. For accurate percent free PSA results, the free PSA assay should be calibrated in agreement with the total PSA assay used, such that a sample that contained only free PSA would be recovered identically in both assays. When the free and total PSA assays are not linked, the ratio of free and total PSA is subject to inaccuracies arising from differences in calibration between the two assays. This situation is especially problematic when assays from two different manufacturers are used because it is unlikely that the two manufacturers collaborated in calibrating their products. Demonstrating this link between assays is not a simple task because samples of 100% free PSA are not readily available. To prepare a sample to approximate this theoretical, 100% free PSA sample, seminal fluid PSA was exhaustively reacted with ACT to deplete the PSA form that would form ACT complexes. In an initial experiment (data not shown), the purified ACTdepleted PSA was added to normal female serum. Further complexation of a fraction of the PSA, presumably by ␣ 2 M, resulted in analytical recoveries between 60% and 90% and made assessment of calibration and analytical recovery difficult. The purified, ACT-depleted PSA was then added to female serum that had been treated to inhibit binding proteins. The recovered values of these samples in both the free and total PSA assays were then used to establish the correlation in calibration between assays. A slope of 1.015 and an r 2 of 1.000 between the recovered values in the Tandem-R free PSA assay and recovered values in the Tandem-R (total) PSA assay demonstrates that these assays provided accurate percent free PSA determinations. Similar results in analytical recovery and assessment of calibration possibly could be obtained by first depleting seminal fluid PSA with both ACT and ␣ 2 M; however, the suitability of this approach has yet to be demonstrated. High-dose hook effect is a known limitation of simultaneous dual-antibody immunoassays. Although a highdose hook effect was seen when total PSA values exceeded 1000 g/L, the clinical ramifications of this are not apparent. At this time, the clinical utility of free PSA has been demonstrated only as a reflex test in conjunction with total PSA in the range of ϳ2-20 g/L total PSA. The percent free PSA determination has less value as total PSA values exceed 10 g/L because of the exceptionally high predictive value of PSA in these ranges [6] . As such, the limitations of assay hook for samples run in a free PSA assay are not critical. However, analytically, the assay will show a hook effect if the total PSA value of the sample exceeds 1000 g/L. Therefore, we recommend that, if for any reason, a sample with a known total PSA in excess of 1000 g/L is run in the free PSA assay, it be diluted first. Other strategies to address hook effect in uncharacterized samples have been described previously [24] .
Proper handling and storage of both commercial controls and patients' samples are essential for reliable clinical results. On the basis of the precision data, changes of Ͻ15% in individual free PSA values would be considered statistically insignificant when the free PSA concentration was Ͻ0.5 g/L, as would changes Ͻ8% when the concentrations were Ͼ0.5 g/L. The lyophilized commercial control preparations showed statistically significant losses in recovery over time after reconstitution. The degree of instability varied by manufacturer. Interestingly, the liquid MAS controls appear to be relatively stable when compared with the reconstituted lyophilized controls. We speculate that the differences between liquid and lyophilized controls may be a result of equilibration between free and bound forms of PSA, and that the liquid controls are at equilibrium, whereas the lyophilized controls may not have been at equilibrium before lyophilization. Therefore, we recommend that, when using lyophilized controls, only freshly-reconstituted material be utilized in free PSA assays. Differences in stability between free and total PSA have also been reported in patients' samples [25, 26] . These studies suggest that for the measurement of free PSA, serum should be processed and refrigerated within 3 h of blood draw and frozen (preferably at Ϫ70°C) if it is to be stored Ͼ24 h. These observations suggest that free PSA is substantially less stable than total PSA is when refrigerated or shipped on ice and that care should be taken in the handling, storage, and shipment of commercial controls and patients' samples.
